Neuren Pharmaceuticals
Home
About Us
Company Overview
Leadership Team
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
Investor Information
Welcome
Share Price Information
Corporate Calendar
Shareholder Services
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Investor presentations, audio, video
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
ASX Announcements
Annual and Interim Reports
Scientific presentations
Investor presentations, audio, video
Email Alerts
Publications
Home
>
News & Reports
>
Investor presentations, audio, video
Font Smaller
Font larger
Print Page
Investor presentations, audio, video
20-Nov-2020
Proactive interview with Jon Pilcher 19 Nov 2020
1-Oct-2020
Morgans interview with Neuren CEO Jon Pilcher 1 Oct 2020
18-Aug-2020
Corporate presentation, 18 August 2020
29-Jun-2020
AGM Chairman's Address and CEO Presentation
29-May-2020
Morgans interview with Neuren CEO Jon Pilcher 29 May 2020
